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subjects: a randomized clinical trial
S. Almoosawi,*a C. Tsang,b L. M. Ostertag,c L. Fyfed and E. A. S. Al-Dujailid
Received 12th March 2012, Accepted 1st July 2012
DOI: 10.1039/c2fo30060eThe association between excess cortisol and various parameters of metabolic syndrome including
hypertension, insulin resistance and dyslipidaemia is increasingly recognised. The present single-blind
randomised placebo-controlled cross-over study compared the effect of polyphenol-rich dark chocolate
(DC) on biomarkers of glucose metabolism, lipid profile, and blood pressure (BP) in females with BMI
$ 25 kg m2 (n ¼ 21) and females with BMI < 25 kg m2 (n ¼ 21). Volunteers consumed 20 g of DC
containing 500 mg polyphenols or a placebo DC with negligible polyphenol-content daily for 4 weeks,
separated by a 2-week washout period. Systolic BP and diastolic BP decreased after 4 weeks of
polyphenol-rich DC. Placebo raised fasting insulin, homeostasis model assessment of insulin resistance
(HOMA-IR) and salivary cortisol, an effect that was significantly different from polyphenol-rich DC
which had a negligible effect on fasting insulin, HOMA-IR and salivary cortisol. Females with BMI $
25 kg m2 responded less favourably to placebo than lean females and consequently had higher fasting
insulin and HOMA-IR, in addition to a lower quantitative sensitivity check index (QUICKI) after
ingestion of placebo compared to polyphenol-rich DC. No significant changes in lipid profile were
observed. This study provides evidence for the metabolic benefits of consuming polyphenol-rich dark
chocolate while demonstrating the possibility of adverse effects occurring with polyphenol-poor
chocolate placebo.Introduction
Obesity is a multifactorial condition linked to numerous car-
diometabolic risk factors including insulin resistance, hyperten-
sion and dyslipidaemia.1,2 In recent years, evidence for the role of
abnormal cortisol metabolism in mediating the association
between obesity and cardiometabolic risk factors, particularly
hyperinsulinaemia and insulin resistance, have been described.2–5
This evidence is based on the central role of cortisol in regulating
glucose and blood pressure (BP) homeostasis, and the ability of
cortisol to promote oxidative stress and decrease nitric oxide
bioavailability.6,7 Current experimental and epidemiological
studies provide evidence for a protective role for polyphenol-rich
dark chocolate (DC) and cocoa polyphenols on markers of
glucose regulation, blood pressure and lipid profile.8–18 ThisaMRC Human Nutrition Research, Elsie Widdowson Laboratory, 120
Fulbourn Road, Cambridge CB1 9NL, UK. E-mail: suzana.almoosawi@
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623; +44 (0)1223 426 356
bHealth & Food Science School of Contemporary Sciences, University of
Abertay, Dundee, UK
cRowett Institute of Nutrition and Health, University of Aberdeen,
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This journal is ª The Royal Society of Chemistry 2012protective role has been ascribed to the antioxidant properties of
DC and cocoa polyphenols and their ability to modulate nitric
oxide bioavailability.14,17 However, few studies have examined
the involvement of the endocrine system in mediating the car-
diometabolic health-effects of polyphenols. We have previously
reported that the consumption of small portions of DC by
overweight and obese individuals improves fasting capillary
glucose and blood pressure levels without significantly altering
urinary cortisol excretion.8 To overcome the limitations of our
previous study and to elaborate on our findings further, the
current study aimed to examine the effect of 4-week consumption
of DC containing 500 mg polyphenols on cardiometabolic risk
factors, cortisol metabolism and antioxidant status across a
range of BMI, the objectives being to establish whether
consumption of polyphenol-rich DC elicits a differential
response between lean and overweight females.
Methods
Design
The study used a single-blind randomised placebo-controlled
cross-over design where each subject acted as their own control.
Following a 1-week run-in phase, eligible subjects were randomly
assigned to receive 20 g DC containing 500 mg polyphenols orFood Funct., 2012, 3, 1035–1043 | 1035
20 g placebo DC. Participants followed each intervention for 4
weeks, after which they were crossed-over to the next interven-
tion separated by a 2-week washout period. The study included
healthy, non-smoking lean (BMI ¼ 18.5–24.99 kg m2) and
overweight females (both overweight, BMI $ 25 kg m2 and
obese, BMI $ 30 kg m2) with no history of diabetes, hyper-
tension or cardiovascular disease. Individuals taking dietary
supplements, BP or cholesterol-lowering drugs, and those with
soy and nut allergies were excluded. Smokers were excluded to
minimise the confounding effect of nicotine consumption on
hypothalamic–pituitary–adrenal axis activity. Participants gave
written consent and completed a lifestyle questionnaire before
being screened for fasting blood glucose, total cholesterol, BP
and BMI to determine their eligibility. The study was conducted
according to the guidelines laid down in the Declaration of
Helsinki. All experiments were performed in compliance with the
relevant laws and institutional guidelines and all procedures were
approved by the university ethics committee.
Diet
Table 1 provides a summary of the nutrient composition of the
polyphenol-rich DC and the placebo used in this study (data
provided by the manufacturer who supplied the chocolate: Barry
Callebaut, Lebbeke, Belgium). The polyphenol-rich DC con-
tained 500 mg of polyphenols, as estimated by the Folin-Cio-
calteu method, and 65.5% of cocoa solids. The 500 mg dose was
selected on the basis of a preliminary study.8 The placebo was a
DC matched for taste, texture, colour and macronutrient
composition to the polyphenol-rich DC, but which contained no
polyphenols. The participants were asked to distribute their DC
dose over the day and to maintain their usual dietary intakes. A
list of polyphenol-rich foods and beverages was provided and
participants were instructed to refrain from eating these products
during the entire study duration.8 Participants were asked to fill
in a 3-day (two weekdays and one weekend) diet and physical
activity diary during the run-in phase and at the end of each
dietary intervention. Diet diaries were analysed for energy andTable 1 Nutritional composition of 20 g of placebo or polyphenol-rich
dark chocolate
Component
Placebo dark
chocolate
Polyphenol-rich
dark chocolate
Total polyphenols (mg)a NGc 500
Epicatechin and catechin (mg)b NG 18.99
Epicatechin and catechin ratio — 9 : 1
Theobromine (mg) 130.00 163.40
Caffeine (mg) 14.30 17.54
Energy (kJ) 425.80 425.80
Total fat (g) 7.34 7.34
Saturated fat (g) 4.62 4.62
Monounsaturated fat (g) 2.46 2.46
Polyunsaturated fat (g) 0.26 0.26
Trans fat (g) 0.04 0.04
Protein (g) 1.34 1.34
Carbohydrate (g) 7.44 7.44
Magnesium (mg) 36.00 42.00
Sodium (mg) 1.24 0.38
Potassium (mg) 340.00 150.00
a Estimated using Folin-Ciocalteu method. b Measured by HPLC. c NG,
negligible.
1036 | Food Funct., 2012, 3, 1035–1043macronutrient intake using Windiet software (Windiet Research,
Univation Ltd, Robert Gordon University, Aberdeen, UK).
Compliance with the study’s protocol was assessed by direct
interviewing, returning of empty chocolate foils and assessment
of diet diaries.Measurements
All tests were conducted at the start and at the end of each
treatment period. Participants were asked to consume the same
diet the day before their appointment and to avoid heavy phys-
ical activity and alcohol 24 h before testing. Blood samples were
obtained by venepuncture following a 12 h fast. Fasting glucose
was measured using a commercial hexokinase assay (Sentinel,
UK). Fasting insulin was measured using a commercial insulin
ELISA kit (Mercodia, Sweden). Homeostasis model assessment
of insulin resistance (HOMA-IR), homeostasis model assessment
of b-cell function (HOMA-b), quantitative sensitivity check
index (QUICKI) and revised-QUICKI were calculated based on
published equations.19–21 Assessment of lipid profile and liver
enzymes (aspartate aminotransferase, troponin) was undertaken
at the Clinical Biochemistry Laboratory, Royal Infirmary of
Edinburgh, Scotland, UK, using an automated platform
(Olympus, UK). Serum non-esterified fatty acids were quantified
using an automated enzymatic colorimetric method (Wako,
Germany) at the Rowett Institute of Nutrition and Health,
Aberdeen, UK. Urinary polyphenol content and antioxidant
status were measured in 24 h urine samples using the Folin-
Ciocalteu method for estimation of total polyphenols22 and
urinary oxygen radical absorbance capacity,23 respectively. A
validated automated A&D Medical UA-767 BP monitor (A&D
medical, San Jose, CA, USA) was used to measure BP after a rest
of 10 min. Three values were taken at 2 min intervals to increase
the reliability of the results. Salivary cortisol and cortisone were
analysed in duplicates using an enzyme-linked immunosorbent
assay (ELISA) according to previously described methods.24,25
The data was then used to calculate the cortisone/cortisol ratio
which serves as an index of 11b-hydroxysteroid dehydrogenase
activity.26 Monitoring the activity of this enzyme helps detect
changes in the peripheral metabolism of cortisol.26Statistical analysis
All statistical analyses were performed using SPSS for Windows,
version 16.0.0 (SPSS Inc, Chicago, IL, USA). Sample size was
calculated based on data from the pilot study8 to permit the
detectionof a 0.5 0.6mmolL1 reduction in fasting glucosewith
a power of (1  b) ¼ 0.8 and a ¼ 0.05 (22 subjects per group).
Continuous normally distributed data are expressed as mean 
SD unless otherwise stated. Differences in baseline characteristics
between the two BMI categories (BMI < 25 kg m2 and BMI $
25kgm2)were examined using an independent sample t-test with
the BMI category as the grouping variable and age, anthropo-
metrical data, biochemical measurements, blood pressure, sali-
vary free cortisol/cortisone ratio, and urinary antioxidant
capacity as the dependent variables.
For multiple comparisons, data were analysed with a three-
factor repeated measure analysis of variance with time (pre- and
post-) and treatment (DC and placebo) as the two within-subjectThis journal is ª The Royal Society of Chemistry 2012
factors and BMI category as the between-subject factor. The
three-factor analysis of variance (ANOVA) detects differences in
response between the two BMI categories, as well as comparing
the effect of the two treatment groups (DC and placebo) and the
pre and post-treatment values of outcome variables. Bonferroni
adjustment was used to account for multiple testing. For statis-
tically significant between-subject effects, data is presented
separately for the two BMI categories. Significant within-subject
effects were further explored by paired Student’s t-test.
Changes in physical activity, energy, and macronutrient intake
were assessed with a mixed between-within subject analysis of
variance with time as the within-subject factor and BMI as the
between-subject factor.
Association between changes in biomarkers of glucose
metabolism, blood pressure and lipid profile, and BMI were
assessed using stepwise regression according to the following
equation: y ¼ (a1x1) + (a2x2) + (a3x3) + a4, in which: y is the
change in outcome from baseline per person per treatment
group, x1is the dummy variable (0 for placebo and 1 for poly-
phenol-rich DC), x2 is the BMI expressed as a continuous vari-
able, x3 is the product term for the dummy variable and BMI,
and a1–4 are the b coefficients.Characteristics of participants
The study included 42 volunteers (41 Caucasian and 1 Hispanic),
ofwhich 21hadanormalBMIrange (meanBMI¼ 21.64 2.23kg
m2), 13were overweight (meanBMI¼ 26.98 1.25kgm2) and8
were obese (mean BMI ¼ 32.23  1.56 kg m2). The flow of
participants through the study is shown in Fig. 1.
Compared to females with BMI < 25 kg m2, females
with BMI $ 25 kg m2 had marginally higher fasting insulin
(P ¼ 0.053) and significantly greater total cholesterol: high-
density lipoprotein ratio (P ¼ 0.043), systolic blood pressure
(SBP) (P < 0.001) and diastolic blood pressure (DBP)
(P < 0.001). The overweight group also had a significantly higher
physical activity level (P < 0.0001), waist circumference
(P < 0.0001), hip circumference (P < 0.0001), waist/hip ratio
(P ¼ 0.023) and percentage body fat (P < 0.0001). Females with
BMI < 25 kg m2 had higher percentage body water than females
with BMI $ 25 kg m2 (P < 0.0001). No differences in other
variables were observed.Fig. 1 Flow of participants through the study.
This journal is ª The Royal Society of Chemistry 2012Glucose metabolism and blood pressure
There was a significant effect of treatment on fasting glucose,
fasting insulin,HOMA-IR,QUICKI, revisedQUICKI, SBP, and
DBP. A significant treatment-by-time interaction was also
observed for these variables suggesting that the change from
baseline across the two treatment groups (polyphenol-rich DC vs.
placebo) was not similar (Table 2). The response to polyphenol-
rich DC and placebo differed by BMI as indicated by the signifi-
cant between-subject effect. Consumption of polyphenol-richDC
for 4 weeks reduced fasting glucose andHOMA-IR from baseline
by 0.58 0.68mmol l1 (P< 0.001 by paired Student’s t-test) and
1.03 0.76 units (P¼ 0.041), respectively in females with BMI$
25 kg m2. There were no significant changes in these parameters
in females with BMI < 25 kg m2 (fasting glucose: P ¼ 0.268;
HOMA-IR P ¼ 0.603). Polyphenol-rich DC did not reduce fast-
ing insulin levels from the baseline in either the overweight (P ¼
0.269) or lean group (P ¼ 0.268). Polyphenol-rich DC decreased
SBP in lean andoverweight females by 3.41 6.08 (P¼ 0.014) and
4.48  7.82 mmHg (P ¼ 0.016), respectively. In contrast, only
females with BMI$ 25 kg m2 experienced a 3.22  3.75 mmHg
reduction inDBP following a 4week consumption of polyphenol-
rich DC (P < 0.001).
Females with BMI $ 25 kg m2 responded less favourably to
placebo DC and consequently had higher fasting insulin (2.73 
5.08 mU l1 increase from baseline; P ¼ 0.023), HOMA-IR
(0.66  1.26 unit increase; P ¼ 0.03) and lower QUICKI (0.01 
0.02 unit decrease; P ¼ 0.033) levels after consumption of the
placebo. This effect was not observed in lean females (P > 0.05).
Differences between BMI categories and between the effect of
polyphenol-rich DC and placebo on glucose metabolism and
blood pressure were further reinforced by the stepwise regression
analysis (Fig. 2 and 3). As observed, polyphenol-rich DC reduced
fasting glucose (P ¼ 0.002) and DBP (P ¼ 0.001) to a greater
extent in subjects with a higher BMI. Insulin, on the other hand,
remained relatively stable at the end of the 4 week treatment with
polyphenol-rich DC. By contrast, the detrimental effects of the
placebo, on insulin (P ¼ 0.014), HOMA-IR (P ¼ 0.001) and
QUICKI (P ¼ 0.005) were more pronounced in females with
elevated BMI than those with a lower BMI.Antioxidant status and glucocorticoid levels
There was a significant effect of treatment and treatment-by-time
interaction on urinary total polyphenols and antioxidant
capacity (Fig. 4). Polyphenol-rich DC increased total poly-
phenols excretion and improved antioxidant status as indicated
by the rise in urinary total polyphenols levels and ORAC,
whereas consumption of placebo increased oxidative stress as
noted by the fall in ORAC.
There was a significant treatment effect on mean daily salivary
cortisol (P ¼ 0.006). Placebo DC raised mean daily salivary
cortisol from 10.52  65.64 nmol l1 to 26.34  40.08 nmol l1,
while polyphenol-rich DC did not alter any of these parameters
(Fig. 5). There were no significant changes in salivary cortisone
or the cortisone/cortisol ratio.
No significant between-subject effects were detected by three-
factor ANOVA suggesting that changes in urinary antioxidant
capacity and salivary glucocorticoids were similar across the twoFood Funct., 2012, 3, 1035–1043 | 1037
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Fig. 2 Body mass index determines the magnitude of the effect of polyphenol-rich dark chocolate (A) and placebo (-) on biomarkers of glucose
metabolism. Regression equations were as follows: (a) placebo y¼ 0.174BMI 3.6621R2¼ 0.033; polyphenol-rich DC y¼0.0542BMI + 0.8192R2¼
0.0086 (b) placebo y ¼ 0.0084BMI + 0.3429 R2 ¼ 0.0024; polyphenol-rich DC y ¼ 0.0592BMI + 1.1467 R2 ¼ 0.0903 (c) placebo y ¼ 0.0003BMI +
0.002R2¼ 0.0047; polyphenol-rich DC y¼ 0.0006BMI 0.0083R2¼ 0.0157 (d) placebo y¼ 0.0054BMI 0.1925R2¼ 0.0094; polyphenol-rich DC y¼
0.0022BMI + 0.053 R2 ¼ 0.0009 (e) placebo y ¼ 0.0365BMI  0.5603 R2 ¼ 0.0235; polyphenol-rich DC y ¼ 0.0283BMI + 0.4364 R2 ¼ 0.0433. Trend
line for polyphenol-rich dark chocolate ( ) and placebo ( ).
Fig. 3 Body mass index determines the magnitude of effect of poly-
phenol-rich dark chocolate (A) and placebo (-) on systolic and diastolic
blood pressure. Regression equations were as follows: (a) placebo y
¼ 0.5134BMI + 12.584 R2 ¼ 0.0852; polyphenol-rich DC y
¼ 0.496BMI + 8.4338, R2 ¼ 0.1126) placebo y ¼ 0.111BMI + 4.2265
R2 ¼ 0.0096; polyphenol-rich DC y ¼ 0.0829BMI  0.1179 R2 ¼
0.0062. Dots stand for change from baseline. Trend line for polyphenol-
rich dark chocolate ( ) and placebo ( ).BMI categories. Consequently, data for urinary antioxidant
capacity and salivary glucocorticoids is presented for the
combined two BMI categories.This journal is ª The Royal Society of Chemistry 2012Additional findings
No significant changes in anthropometric data were observed
following polyphenol-rich DC consumption or placebo.
However, a significant difference in body weight was detected
between the placebo and the active polyphenol-rich DC group
at the end of the 4 week treatment (Table 2). Additional anal-
yses using a paired Student’s t-test demonstrated that there was
a difference of 0.57  1.08 kg between weight values at the end
of the 4 week treatment with placebo compared to post-poly-
phenol-rich DC in overweight females (P ¼ 0.011) but not in
lean females (difference in weight between post-placebo and
post-DC ¼ 0.06  1.78 kg; P ¼ 0.088). The inclusion of the
change in body weight as a covariate in three-factor ANOVA or
regression did not alter the main effects of treatment (data not
shown).
There were no significant changes in energy or macronu-
trient intake from baseline or between polyphenol-rich DC
and placebo (Fig. 6). No significant changes in lipid profile,
liver enzymes, or physical activity from baseline or between
polyphenol-rich DC and placebo were found (data not
shown).Food Funct., 2012, 3, 1035–1043 | 1039
Fig. 4 Changes in total urinary polyphenol content and oxygen radical
absorbance capacity (ORAC) after 4 weeks of polyphenol-rich dark
chocolate (A) and placebo (-) (n ¼ 41). Data are expressed as means 
SEM.
Fig. 5 Effect of polyphenol-rich DC (A) and placebo (-) on mean
daily salivary cortisol, cortisone and cortisone/cortisol ratio (n ¼ 40).
Results represent mean  SEM of three salivary collection obtained
in morning (9.00–10.00 am), afternoon (12.00–1.00 pm) and evening
(4.00–5.00 pm). All samples were analysed in duplicates.Discussion
The present study demonstrates that a 4 week consumption of
DC containing 500 mg polyphenols by lean and overweight
females reduces BP and improves glucose regulation as indicated
by the reduction in fasting glucose and HOMA-IR. Such findings
are consistent with our preliminary data,8 epidemiological10 and
intervention studies on healthy volunteers,11 hypertensives9 and
glucose-intolerant hypertensives.12 The data are also in accor-
dance with the most recent findings of Davison et al.13 who
reported beneficial effects of polyphenol-rich cocoa on car-
diometabolic markers in subjects with BMI $ 25 kg m2. More
importantly, the current study demonstrates that overweight and
obese subjects respond more effectively to the hypoglycaemic
and hypotensive properties of polyphenol-rich DC than their
lean counterparts. To our knowledge, this is the first study that
allows the direct comparison of the effect of polyphenol-rich DC
on glucose, lipid and BP between the two BMI categories. Such
differences in response may be attributed to the raised metabolic
risk factors seen in individuals with BMI$ 25 kgm2 which were
predicted in the current study by the higher baseline waist
circumference, waist/hip ratio, total cholesterol: high-density
lipoprotein ratio, and BP compared to lean individuals.
In contrast to previous human studies, no significant changes
in fasting insulin were observed in this trial following
consumption of polyphenol-rich DC. Some animal studies have
failed to report any improvements in insulin in some models of
obesity but not in others, which could indicate that the under-
lying cause of insulin resistance may dictate a subject’s respon-
siveness to polyphenol-rich DC. Alternatively, the use of a more
robust study design which included a DC placebo rather than a
white chocolate placebo could have eliminated any possible
effect of varying magnesium and theobromine content between
the active DC and the placebo. This implies that, unlike other1040 | Food Funct., 2012, 3, 1035–1043studies which did not control for differences in macronutrient
and micronutrient content, any changes in the assessed param-
eters in our study can be directly related to the presence of DC
polyphenols rather than other DC components. The latter could
be further supported by the significant rise in urinary antioxidant
capacity seen following ingestion of polyphenol-rich DC.
In the present intervention, reductions in SBP and DBP of
4.17 and 2.29 mmHg, respectively, were observed. These values
are consistent with a recent meta-analysis of 10 randomised
controlled trials involving 297 volunteers which demonstrated
that, on average, polyphenol-rich DC and cocoa reduce SBP and
DBP by 4.5 and 2.5 mmHg, respectively.14 However, whenThis journal is ª The Royal Society of Chemistry 2012
Fig. 6 Energy and macronutrient intake in lean females (n ¼ 21) and overweight females (n ¼ 21) at baseline and during the polyphenol-rich DC and
placebo intervention.comparing changes in BP in the main study to the preliminary
DC study,8 it can be observed that the magnitude of reduction in
SBP and DBP was lower at the end of the 4 week main DC
intervention (SBP  4.17 mmHg from baseline, DBP  2.29
mmHg from baseline) than at the end of the 2 week preliminary
study (SBP  6.98 mmHg from baseline, DBP  5.62 mmHg
from baseline). This is partially in agreement with the afore-
mentioned meta-analysis wherein Desch et al.14 demonstrated
greater reductions in SBP and DBP in short-term 2 week trials as
opposed to long-term 4–18 week interventions, suggesting that
adaptation might occur to high polyphenol doses over time.
Regardless of the latter, small improvements in BP such as
observed in our study could have important implications to
population prevalence of cardiovascular disease. In the Zutphen
Elderly cohort, the highest tertile of cocoa consumption was
related to a 3.7 and 2.1 mmHg reduction in SBP and DBP,
respectively, compared to the lowest tertile of cocoa consump-
tion. This cocoa-related reduction in BP was linked with a 45 and
50% reduction in long-term risk of cardiovascular disease and
all-cause mortality, respectively. More recently, data from the
European Prospective Investigation into Cancer and Nutrition,
involving 19 357 people, have shown that even smaller reduction
of 1.0 mmHg in SBP and 0.9 mmHg in DBP, induced by
moderate chocolate consumption, could decrease the long-term
risk of myocardial infarction and stroke by 39%.This journal is ª The Royal Society of Chemistry 2012The absence of an effect of polyphenol-rich DC on lipid profile
is in contrast to previous research9,12,15,16 and meta-analytical
data.17 However, it is consistent with some studies that did not
observe any changes in lipid profile after ingestion of polyphenol-
rich DC.11,18 Most previous studies that reported changes in lipid
profile included participants who had a high lipid profile and
who consumed 100 g DC containing 500 mg polyphenols.9,12
Thus, the lack of a significant effect in our study could be
attributed to the normal lipid levels of our study’s population or
differences in the composition of the chocolate products used.
The present study adds to current knowledge by demon-
strating that overweight and obese individuals could be more
adversely affected by the consumption of polyphenol-poor DC
than lean individuals, as indicated by the significant rise in
fasting insulin, HOMA-IR, and the marginal decline in QUICKI
following placebo. In fact, using the linear regression equations,
it could be estimated that a 4 week consumption of polyphenol-
deficient DC by a woman with a BMI¼ 30 kg m2 could increase
fasting insulin and HOMA-IR by 1.56 mU l1 and 0.53 units,
respectively, compared to an estimated 0.17 mU l1 and 0.24
unit increase in insulin and HOMA-IR in a woman with a BMI¼
22 kg m2. Such changes in insulin sensitivity have not been
reported by previous studies possibly due to the use of lean
individuals, the short duration of the trials, and the use of
tailored iso-caloric diets.9,11,12,18 Nevertheless, our findings areFood Funct., 2012, 3, 1035–1043 | 1041
consistent with studies reporting that polyphenol-poor chocolate
and cocoa-flavoured food products have an insulin index 50–60%
higher than that predicted by their glycolic index.27Consumption
of commercially available cocoa has also been shown to enhance
postprandial insulin secretion in lean young adults.28 This
hyperinsulinaemic effect has been attributed to the presence of
several insulinotropic compounds in cocoa and chocolate
including stearic acid, caffeine, theobromine, serotonin, phenyl-
ethylamine, cannabinoid-like fatty acids and amino acids like
leucine, phenylalanine and arginine.28 However, to our knowl-
edge, no study has as yet identified the exact component
responsible for the hyperinsulinaemic effect of commercially
available cocoa or chocolate. Moreover, we did not have any
information regarding the chemical composition of the placebo
or the process by which it is produced. This would have helped
clarify whether the manufacturing process could have altered the
chemical matrix of the placebo rendering it more harmful to
health. Regardless of this, our findings raise concern considering
the widespread consumption and availability of polyphenol-
deficient chocolate on the market.
In addition to the hyperinsulinaemic effects, placebo DC
increased oxidative stress and salivary cortisol levels in both lean
and overweight females. These findings were in contrast to the
improved antioxidant status and unaltered cortisol levels seen
following treatment with polyphenol-rich DC. Cocoa butter is
known to induce oxidative stress both in vitro and in vivo.29High-
fat feeding has also been shown to stimulate basal and stress
induced hypothalamic activity in animal studies.30,31 Moreover,
in humans, high-fat low-carbohydrate diets,32mixed meals,33 and
lipid and insulin infusions34 have been shown to increase cortisol
production. Together, this evidence may imply that in the
absence of polyphenols, high-fat products such as chocolate may
adversely affect metabolism. Consequently, the importance of
polyphenols may lie in their ability to counteract the deleterious
effects of high-fat and polyphenol-deficient products as opposed
to providing any additional hormonal benefits.
One of the main limitations of the present study is the observed
rise in body weight seen at the end of the placebo intervention in
the overweight group, which may have accounted for the rise in
insulin resistance seen following the consumption of placebo.
Although we did not observe any changes in energy intake or
physical activity, under-reporting of energy intake cannot be
excluded in overweight individuals and may have accounted for
the observed rise in body weight. The placebo also contained a
high amount of fat and sugar and no polyphenols. Given the
known association between excess cortisol and oxidative stress7
and the ability of cortisol in the presence of hyperinsulinaemia to
promote fat accumulation,35 it could be speculated that the rise in
body weight in the overweight group following treatment with
polyphenol-deficient DC may have occurred due to the detri-
mental effect of the placebo on insulin and cortisol metabolism.
This hypothesis deserves further research considering the ability
of polyphenols to modulate glucocorticoid metabolism36,37 and
the potential implications such findings may have in forwarding
our understanding of the association between diet and disease.
Recently, several experimental studies in rodents have shown
that polyphenol-rich cocoa can promote thermogenesis and
inhibit high-fat diet-induced obesity,38 and that cacao-derived
epicatechin can promote the oxidative capacity of muscle.391042 | Food Funct., 2012, 3, 1035–1043Recent epidemiological evidence has also found that frequent
consumption of chocolate is inversely associated with BMI.40
This evidence, combined with the findings from the current
study, suggests that further research is needed to understand the
role of polyphenols in modulating metabolism and weight
regulation.
Conclusions
In conclusion, the present study demonstrates that overweight
females respond more favourably to the glucose- and blood
pressure-lowering effects of polyphenol-rich dark chocolate than
females with a normal BMI range. Polyphenol-rich dark choc-
olate did not affect cortisol metabolism. However, an adverse
effect of polyphenol-deficient dark chocolate on insulin sensi-
tivity, antioxidant status and cortisol metabolism was observed
suggesting that the importance of polyphenols in chocolate may
lie in their ability to avoid the adverse effects of polyphenol-
deficient dark chocolate. This suggests the need for further
research to improve our understanding of the relation between
polyphenols and health.
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